In a filing, Immunocore Holdings plc ADR revealed its HEAD OF R&D Berman David M unloaded Company’s shares for reported $1.26 million on Dec 04 ’25. In the deal valued at $40.26 per share,31,341 shares were sold. As a result of this transaction, Berman David M now holds 0 shares worth roughly $0.0.
Then, Berman David M sold 572 shares, generating $22,960 in total proceeds. Upon selling the shares at $40.14, the HEAD OF R&D now owns 0 shares.
Before that, Berman David M sold 69,404 shares. Immunocore Holdings plc ADR shares valued at $2,784,488 were divested by the HEAD OF R&D at a price of $40.12 per share. As a result of the transaction, Berman David M now holds 0 shares, worth roughly $0.0.
UBS upgraded its Immunocore Holdings plc ADR [IMCR] rating to a Buy from a a Sell in a research note published recently. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in late October with a ‘”an Overweight”‘ rating.
Price Performance Review of IMCR
On Friday, Immunocore Holdings plc ADR [NASDAQ:IMCR] saw its stock jump 1.83% to $33.35. Over the last five days, the stock has gained 1.06%. Immunocore Holdings plc ADR shares have risen nearly 13.28% since the year began. Nevertheless, the stocks have fallen -3.92% over the past one year.
How much short interest is there in Immunocore Holdings plc ADR?
A steep rise in short interest was recorded in Immunocore Holdings plc ADR stocks on 2025-12-31, growing by 0.96 million shares to a total of 9.52 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 8.56 million shares. There was a rise of 10.04%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 27, 2025 when Deutsche Bank began covering the stock and recommended ‘”a Buy”‘ rating along with a $65 price target.
